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Prophylactic use of the silver-acetate–coated graft
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Eike Sebastian Debus, MD,a,b Würzburg and Hamburg, Germany
Objective: Silver-coated vascular polyester prostheses were developed not only for the treatment of prosthetic graft
infections, but also for use as prophylaxes. Although some studies describe the use of these prostheses in cases of infection,
there are few data on their prophylactic use. This study compares the performance of the InterGard Silver polyester graft
(Intervascular, Datascope, Inc, La Ciotat, France) with that of standard prostheses in routine use.
Methods: This retrospective study included all patients who received alloplastic bypass for treatment of arterial occlusive
disease at the University Hospital in Würzburg from January 1996 to December 2006. The courses of disease were
analyzed by examining the medical records. Follow-up research documented long-term results.
Results: The cases of 913 patients were analyzed (430 silver grafts, 483 standard grafts). Indications for the operations
were claudication (silver: 136, nonsilver: 212), rest pain (49/65), tissue loss (135/148), and acute occlusion (110/58).
Prosthetic implantation was performed in the aorto-iliaco-femoral position (silver: 93, nonsilver: 146), in the femoro-
distal position (309/304), and as multilevel reconstruction (28/33). With regard to perioperative complications, the two
groups did not differ significantly. There were no silver release-related complications, such as colored exudation or wound
staining. Mean follow-up time was 56.7 1.6 (SEM) months. When corrected for redo procedures, stage of disease, and
type of reconstruction, both materials performed equally well: 5-year patency for claudication: silver 91%, nonsilver 95%,
femorodistal 47%/41%; 5-year patency for critical ischemia: aortofemoral 88%/93%, femorodistal 31%/35%; 5-year limb
salvage (critical ischemia): aortofemoral: 78%/79%; femorodistal: 59%/67%. Graft infections (Szilagyi grade III) were
detected in 59 patients (6.4%; silver: n  32, 7.4% vs control: n  27, 5.5%; P  .28) after an average of 321  96 days.
One infection occurred out of 93 aortofemoral operations with the silver prosthesis (1.1%) compared to 4.1% (6/146) in
the control group (P .17). For patients with femorodistal grafts, silver exhibited an infection rate of 9.4% compared to
5.9% (P .11). In the multiple regression analysis, two factors influenced the rate of a graft infection significantly: wound
healing impairment and revision after bypass implantation. Silver did not prevent a subsequent bypass infection in these
cases (silver: 18.1% vs 12.5%, P  .27).
Conclusion: The silver-coated prosthesis did not differ from standard materials. Silver had no significant effect on the risk
of graft infection. Our study showed good results with the silver prosthesis in the aorto-iliaco-femoral position, but in
cases of femorodistal grafting, a reduction of prosthetic infections was not achieved. The silver grafts did not prevent
subsequent infections in cases of tissue loss or postoperative local complications. ( J Vasc Surg 2009;50:790-8.)The first silver-acetate–coated graft (InterGard Silver;
Intervascular, Datascope, Inc, La Ciotat, France) was intro-
duced to the market more than 9 years ago. According to
the product description, it was “designed for routine use in
vascular bypass procedures”. In early 2006, another silver-
coated device, the B. Braun Silver Graft, became available (B.
Braun, Inc, Melsungen, Germany). Whereas the silver de-
grades from the InterGard conduit within 4 weeks*, the
*According to the manufacturer, “the silver release profile is designed to be
most active during the initial 24 hours postimplant, with continuous and
substantial release for a 7-day period” Source: http://www.intervascular.
com/eng/products/pdf/intergard_silver_brochure.pdf (cited April
2006).
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790Braun graft has a slower release, lasting for more than a year.1
Silver prostheses are more expensive than their uncoated
counterpart: according to list prices published by the manu-
facturer (Intervascular), the silver-acetate–coated prosthesis
costs 14-16% more than the uncoated implant.
Although the effectiveness of silver-coated grafts has
been shown in-vitro, there is still controversy concerning
in-vivo animal studies.1-3 These studies, where the silver-
acetate–coated polyester prostheses performed less well
than rifampin-soaked grafts, have been criticized.4,5 The
InterGard Silver prostheses were sterilized in an autoclave
before being implanted in animals. Such procedures, which
are not allowed according to the manufacturer, may alter
the coating; furthermore, the infection model chosen was
said to be unrealistic, as the bacterial strain used was highly
sensitive to rifampin and the strain itself could not be
identified by reference number.4,5
Some authors have reported the successful treatment of
infected grafts with in-situ reconstruction using silver
grafts.6,7 Despite the implementation of enhancements in
surgical techniques (eg, the perioperative use of antibiotics
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infection (Szilagyi grade III) of an alloplastic vascular graft
remains a major problem, and some studies report increas-
ing incidence in recent years.8
Study objective. The aim of the study was to assess the
short- and long-term performance of silver-acetate–coated
polyester prostheses in comparison with nonsilver grafts.
Complications, mortality, patency, limb salvage, and devel-
opment of graft infection served as essential parameters.
MATERIALS AND METHODS
The study was done in the Department of Vascular and
Endovascular Surgery at University Hospital in Würzburg,
Germany. In a retrospective analysis, all patients that re-
ceived alloplastic prosthesis in the aortofemoral or femoro-
distal position from January 1996 until December 2006
were identified by examining the documentation of the
operating unit. The InterGard Silver graft was introduced
to our unit in 1999. Aneurysms, prosthetic infections as
diagnosis, and rarely-performed surgeries were excluded.
During that time period, a Dacron graft was the material of
choice for aortofemoral and Dacron graft or polytetrafluo-
roethylene (PTFE) for above-knee femorodistal bypasses.
For below-knee reconstructions, the great saphenous vein
was preferred. In absence of this vein, or to reduce opera-
tion time in emergency cases, or in old patients, a Dacron
graft or PTFE was used.
The case files were retrieved, and the following data
were collected: patient-dependent factors, pre-, intra-, and
postoperative details, and further therapies. Wound healing
disturbance was noted, if the incision wound did not heal
properly (wound dehiscence). A lymphatic fistula was
stated if a lymphocele developed or wound secretion was
prolonged (7 days). When the study was carried out in
December 2007, a follow-up examination was scheduled.
The patients were invited to undergo an exact examination.
Graft patency was documented by palpable pulse and du-
plex ultrasound scan. If the patient refused to come to the
hospital, a telephone interview was conducted, or the fam-
ily doctor was questioned. For those patients for whom no
Table I. Characteristics of the study group (silver) and th
Parameter
Patient
characteristics
A
(n 
Basic data Age 68.8
Male-female ratio 2.3
Indication Claudication 348 (3
Rest pain 114 (1
Tissue loss 283 (3
Acute occlusion 168 (1
Previous procedure
on the vessel
Any procedure 298 (3
Bypass in groin 134 (1
PTA 112 (1
TEA 54 (5
PTA, Percutaneous transluminal angioplasty; TEA, thrombendarterectomy
Statistics: for nominal data, the 2 test was used, for numeric data, t test.actual information could be obtained, the status of the lastexamination was recorded (“lost to follow-up”). The
study’s main endpoint was development of graft infection
(Szilagyi grade III – involvement of the arterial implant).
Graft infection was usually suspected clinically and con-
firmed by computed tomography (CT) scan. Secondary
endpoints were mortality, bypass patency, and limb salvage.
The data were collected using MicroSoft Excel (Red-
mond, Wash). Statistical evaluation was carried out using
SPSS software for Windows v. 16 (SPSS Inc, Chicago, Ill).
In addition to descriptive data analysis (mean, SE), other
tests were performed. To compare nominal variables, the 2
test was employed. For metric data, such as age, the samples
were analyzed by t test for independent samples (two
samples) or analysis of variance (ANOVA) (2 samples).
Binary logistic regression analysis was used to estimate the
importance of each factor. Patency, limb salvage, and sur-
vival data were demonstrated using the Kaplan-Meier
method and the log-rank test. The level of significance was
set at   .05.
RESULTS
Until December 2006, 430 patients received a silver
graft for acute or chronic arterial occlusion of the lower
limbs (study group). From 1996 until December 2006,
483 additional prostheses without silver were implanted in
the aortofemoral and/or femorodistal position (control
group). The majority of these grafts had been implanted
before the year 2001 (n  335, 69.4%).
Short-term results. The control group and the study
group differed in several parameters (Table I). For the silver
group, patients were older, and more females had surgery.
Although the percentage of cases with chronic critical limb
ischemia (rest pain and tissue loss/gangrene, Rutherford
stages 4, 5, and 6) was comparable for the groups, signifi-
cantly more patients with claudication had surgery in the
control group. With acute occlusion (limb threatened,
Rutherford stages 2a and 2b), more patients had surgery in
the study group. Because of the retrospective character of
the study, it was not possible to distinguish the different
clinical grades 2a and 2b. Diabetes was found in 356
trol group (nonsilver)
Silver group
(n  430)
Control group
(n  483) P value
69.5  0.48 67.9  0.51 .029
1.6:1 2.9:1 .015
) 136 (31.6%) 212 (43.8%) .001
) 49 (11.4%) 65 (13.5%) .368
) 135 (31.4%) 148 (30.6%) .830
) 110 (25.6%) 58 (12.0%) .001
) 166 (38.6%) 132 (27.3%) .001
) 82 (19.1%) 52 (10.8%) .001
) 78 (18.1%) 34 (7.0%) .001
34 (7.9%) 20 (4.1%) .001e con
ll
913)
 9.8
:1
8.1%
2.5%
1.0%
8.4%
2.6%
4.7%
2.3%
.9%)patients (39.0%), hypertension in 691 (75.7%), cardiac
trol gr
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in 75 (8.2%). Fifty-four percent (498) were smokers. The
vessels of 298 patients (32.6%) had been treated before, up
to 7 times (silver: 166, 38.7%; control: 132, 27.3%; P 
.001; Table I). The groin had been used for a previous
bypass placement in 134 cases (silver: 82, 19.1%; control:
52, 10.8%; P  .001). An actual occlusion of one of these
bypasses led to implantation of a prosthesis in 93 cases
(silver: 57, 11.8%; control: 36, 7.4%; P  .001).
The surgeries performed are listed in Table II. Silver
prostheses were implanted predominantly in patients with
limb-threatening ischemia, particularly in the femorocrural
position. Of the 259 femorocrural reconstructions, 196
(76%) received a vein cuff for the distal anastomosis (silver:
131/142, 92%; control: 65/117, 55.5%; P  .001).
The rate of intraoperative complications did not differ
Table II. Indications and bypass types for the 913 patient
Indication/position of the graft
All
(n  913)
Clau
(n
Aortobifemoral (n  186)
silver 53
nonsilver 133
Aorto-iliaco-femoral1 (n  53)
silver 40
nonsilver 13
Femoropopliteal (AK) (n  249)
silver 119
nonsilver 130
Femoropopliteal (BK) (n  105)
silver 48
nonsilver 57
Femorocruralpedal (n  259)
silver 142
nonsilver 117
Multilevel2 (n  61)
silver 28
nonsilver 33
Sum
silver 430
nonsilver 483
AK, Above-knee; BK, below-knee.
Depicted are the absolute numbers for the study group (silver) and the con
1Ipsilateral or cross-over; 2aorto-iliaco-femoral and femorodistal.
Table III. Intraoperative complications and relevant local
Complication
All
(n  913)
Intraoperative complications
Thrombotic occlusion 76 (8.3%)
Injury of intestine, ureter, or bladder 4 (0.5%)
Cardiac 4 (0.5%)
Local postoperative complications
Subcutaneous infection/hematoma 39 (4.2%)
Lymphatic fistula 129 (14.1%)
Wound healing disturbance 148 (16.2%)
Revision due to local complications 133 (14.3%)
NC, Not calculated because of low number.
Statistics: for nominal data, the 2 test was used, for numeric data, t test.significantly between the two groups. Thrombotic occlu-sions were found in 7.7% of the silver prostheses and 8.9%
of the control group (Table III).
During the first 30 days after the operation, severe
pulmonary problems (mainly pneumonia) were the most
common of the systemic complications (n  39, 4.3%).
Renal complications (temporary renal failure) occurred in
35 patients (3.8%). Stroke (n  4, 0.6%) and clinically
apparent heart attack (n  10, 1.1%) were seldom experi-
enced. A heparin-induced thrombopenia type II was no-
ticed in 4 patients (0.4%).
Regarding local complications, lymphatic fistulas oc-
curred in noticeable numbers (n 129, 14.1%, comparable
for both groups, Table III). Wound-healing disturbances/
infections were noticed in 148 (16.2%) and 39 (4.2%)
patients, respectively, again without noteworthy differences
between groups. A total of 133 operations were performed
o received an alloplastic bypass
ion
)
Rest pain
(n  114)
Tissue loss
(n  283)
Acute occlusion
(n  168)
7 13 9
11 32 10
7 3 12
0 1 5
8 35 12
4 34 15
8 23 8
10 28 2
16 52 60
34 46 20
3 9 9
6 7 6
49 135 110
65 148 58
oup (nonsilver).
operative complications
Silver group
(n  430)
Control group
(n  483) P value
33 (7.7%) 43 (8.9%) .582
3 (0,6%) 1 (0,2%) NC
2 (0,5%) 2 (0,5%) NC
16 (3.7%) 23 (4.8%) .540
57 (13.3%) 72 (14.9%) .535
72 (16.7%) 76 (15.7%) .503
59 (13.7%) 74 (15.2%) .555s wh
dicat
 348
24
80
18
7
64
77
9
17
14
17
7
14
136
212postas a result of local complications during the first hospital
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as colored secretion or wound staining did not occur.
A total of 49 patients died during their hospital stay
(5.4%), 3 of them because of an early bypass infection (2 in the
silver group). For patients with intermittent claudication (pe-
ripheral arterial occlusive disease [PAOD] Rutherford stage
3), none of the patients in the silver group died, compared
with 3 in the control group (1.4%). Attributed to the aortic
position of proximal anastomosis, mortality was 9.9% in the
silver group, compared with 5.5% in the control group. For
the patients with proximal anastomosis in the groin, mortality
was lower for the silver group (3.6% vs 4.9%). None of these
differences were statistically significant.
Long-term results. The mean follow-up time was
56.7  1.6 (SE) months. Eighty-three patients refused to
meet in person, so the information was obtained by telephone
in these cases. A total of 102 patients were lost to follow-up
(11%) after an average time of 28.5  2.3 months, and 301
(33%) patients died after dismissal. Most deaths were related
to cardiac disease (152 patients, 51,8%), followed by tumors
(57, 18.9%), and sepsis (11, 3.6%) because of a subsequent
bypass infection (see below). In the remaining cases, death was
due to renal failure, liver failure, ileus, or stroke, or could not
be determined. Survival rate differed significantly depending
on the indications (P .001), with the lowest 5-year survival
rate among patients with gangrene (43.6%  3.8) and the
highest among those with intermittent claudication (77.9%
2.8). Five-year survival for patients with rest pain (68.6% 
4.9) was slightly higher than that for those with acute occlu-
sion (63.4% 4.7).
A total of 359 bypass occlusions occurred (silver group:
191; control group: 168; mean time until occlusion: 364 
34.7 days). In most patients, the reason for thrombosis was
bad outflow. Fig 1, a, shows overall primary patency rates.
Claudication exhibited significantly better patency (5-year
patency: 70.1%  3.1), while rest pain (45.0%  5.1), tissue
loss (48.7%  4.0), and acute occlusion (42.4%  5.0) had
comparable results (Fig 1, a). Comparing all prostheses to-
gether, we found that the control group exhibited a better
patency than the silver group (5-year patency: 53.8% 3.9 vs
36.9% 4.2, respectively). To exclude bias, we calculated the
5-year patency or limb salvage for subgroups. There were
more redo procedures (in particular for bypass occlusion) in
the silver group, so we confined the calculation to the cases in
which no bypass had been implanted before. As shown in Fig
2, a, patency in claudication was still better for the control
group (5-year patency: 81% 3.5 vs 57% 5.7). This may be
attributed to the fact that there were substantially more aorto-
(bi-)femoral procedures in the nonsilver group. Fig 2, b,
depicts patency for those cases with aortofemoral prostheses
for claudication, with both groups exhibiting comparable
patency (control: 95%  2.7 vs silver: 91%  6, not signifi-
cant). For cases with critical ischemia, the patency for the
aortofemoral bypasses was lower (control: 93% 2.8 vs silver
88% 7.1, not significant). The femorodistal reconstructions
demonstrated comparable results for both groups in the pa-
tients with claudication (silver: 47%  6.8 vs control 41% 
9.9, not significant) and in the cases with chronic criticalischemia (Fig 2, c; silver: 31%4.7 vs control: 35%4.5, not
significant).
By definition, limb salvage must be calculated for pa-
tients suffering from critical ischemia (n  565). In this
group, 112 legs had to be amputated, 39 of them within 30
days after graft implantation. In contrast to the patency
rate, the limb salvage rate differed between the indications
of rest pain and tissue loss/acute occlusion significantly
(Fig 1, b). The overall 5-year limb salvage rate for patients
with limb-threatening limb ischemia was significantly lower
for the silver group (58.2% 3.7 vs 74.6% 3.2; P .04,
Fig 3, a). We examined the rates of different diagnoses and
types of surgeries. Again, as shown for patency, the silver
and control groups did not differ significantly in the sub-
group analysis. As can be seen in Fig 3, limb salvage rates for
those cases with aortofemoral (silver: 78%  7.9 vs control
Fig 1. Overall primary patency and limb salvage rates for the
different indications (Kaplan-Meier). a, The patency rate for clau-
dication is significantly better, while the curves for rest pain, tissue
loss, and acute occlusion do not differ. b, In contrast, rest pain has
a significantly better limb salvage rate compared to tissue loss and
acute occlusion. Vertical dotted lines: 1 and 5 years.79%  6.3; Fig 3, b) and femorodistal (Fig 3, c) are
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silver and nonsilver groups in patients with claudication (all oper-
ations). The control group seems superior. b, Subgroup analysis:
patency rate for aorto-(bi-)femoral prostheses in claudicants, pre-
vious procedures on the vessel excluded. There is no difference
between the groups. c, In femorodistal prosthesis implanted criti-
cal limb ischemia, the patency rates are similar. Statistic: log-rank
test. Vertical dotted lines: 1 and 5 years.Fig 3. Limb salvage rates for patients with limb at risk (Kaplan-
Meier). a, Overall performance. Again, the results for the silver
group were inferior to the nonsilver group. b, Subgroup analysis:
aorto-(bi-)femoral prostheses; there is no difference between the
groups. c, Femorocrural prostheses (without redo procedures) did
not show a significant difference. Statistic: log-rank test. Dotted
lines: 1 and 5 years.
lver) a
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c). This alleged discrepancy between overall and detailed
limb salvage can be explained by the fact that there were
considerably more femorodistal procedures in the silver
group (like stage migration or “Will Rogers Phenomenon”
in cancer statistics).
A graft infection (Szilagyi grade III) was detected in 59
patients (6.4%), without statistical difference between the
groups (silver: n  32, 7.4% vs control: n  27, 5.5%; P 
.28). Of these 59 patients, 14 died in consequence of that
infection (mortality 23.7%; silver: n  9, 28.1%; vs control:
n 5, 18.5%; P .39). Six patients died due to other reasons
(3 of cardiac disease, 2 of tumors, and 1 of stroke) and 39
patients were alive without signs of infection when the
follow-up study was conducted. The mean time until the graft
infection became evident was 321  96 days. A total of 18
infections (6 silver, 12 control) occurred during the first 30
days. We conducted a univariate ANOVA to determine which
parameters influenced the development of bypass infection.
No influence was seen by gender, age, acute operation, hyper-
lipidemia, diabetes, high blood pressure, smoking, adipositas,
renal insufficiency, dialysis, cardiac disease, stroke, liver dis-
ease, pulmonary disease, number of risk factors, preceding
percutaneous transluminal angioplasty (PTA), number of
preceding procedures, preceding thrombendarterectomy,
alloplastic material (PTFE/Dacron graft, silver), time of op-
eration, anastomotic technique, lymphatic fistula, or postop-
erative pulmonary/renal/cardiac failure. Statistically relevant
factors were the following:
1. Indication (claudication vs critical limb ischemia) (P 
Table IV. Subsequent bypass infections for the different i
an alloplastic bypass
Indication/position of the graft
All
(n  913)
Claudica
(n  34
Aortobifemoral (n  186)
silver 1 (1.9%) 0
nonsilver 5 (3.8%) 2 (2.5%
Aorto-iliaco-femoral1 (n  53)
silver 0 0
nonsilver 1 (7.7%) 1 (14.3
Femoropopliteal (AK) (n  249)
silver 7 (5.9%) 0
nonsilver 6 (4.6%) 2 (2.6%
Femoropopliteal (BK) (n  105)
silver 8 (16.7%) 1 (11.1
nonsilver 5 (8.8%) 1 (5.9%
Femorocruralpedal (n  259)
silver 14 (9.9%) 3 (21.4
nonsilver 7 (6.0%) 1 (5.9%
Multilevel2 (n  61)
silver 2 (7.1%) 1 (14.3
nonsilver 3 (9.1%) 2 (14.3
Sum
silver 32/430 (7.4%) 5/136 (3
nonsilver 27/483 (5.6%) 9/212 (4
AK, Above knee; BK, below knee.
Depicted are the absolute numbers and percentages for the study group (si
1Ipsilateral or cross-over; 2aorto-iliaco-femoral and femorodistal..019);2. Type of bypass (aortic/iliac vs femoral) (P  .037);
3. Existing bypass in the groin (P  .042);
4. Wound healing disturbance (P  .001);
5. Postoperative local subcutaneous infection or bleeding
(P  .001);
6. Postoperative revision (local) (P  .002).
Factors 1 & 2. Indication and type of bypass: analysis of
the infection rate for all grafts related to indication showed
that claudication had significantly fewer infections than the
other indications (P .012). The two groups did not differ
significantly with regard to the indications or type of bypass
reconstruction (Table IV). One infection occurred out of
93 aortofemoral operations with the silver prosthesis
(1.1%) compared to 4.1% (6/146) in the control group
(P  .17). For patients with femorodistal grafts, silver
exhibited an infection rate of 9.4% compared to 5.9% (P 
.11).
Factor 3. Existing bypass in the groin: the reason for
the use of silver might be the redo operation in the groin.
For patients who had undergone a previous procedure
(PTA, thrombendarterectomy [TEA], or bypass), the in-
fection rate was higher for the silver group than for the
control group (Fig 4, a, b), statistically significant for pre-
vious bypass implantation.
Factors 4, 5, & 6. Local complications: another reason
for the implantation of silver might be the prevention of
infection in case of a local complication (prophylaxis). In
our study, subsequent infections after postoperative local
complications like wound healing disturbance were not
tions and bypass types of the 913 patients who received
Rest pain
(n  114)
Tissue loss
(n  283)
Acute occlusion
(n  168) P value
.541
0 1 (7.7%) 0
0 3 (9.4%) 0
.382
0 0 0
0 0 0
.434
0 6 (17.1%) 1 (8.3%)
0 2 (5.9%) 2 (13.3%)
.177
2 (25%) 4 (17.4%) 1 (12.5%)
2 (20%) 2 (7.1%) 0
.182
1 (6.2%) 3 (5.8%) 7 (11.7%)
4 (11.8%) 2 (4.3%) 0
.579
0 1 (11.1%) 0
0 1 (14.3%) 0
.158
3/49 (6.1%) 15/135 (11%) 9/110 (7.6%)
6/65 (9.2%) 10/148 (6.8%) 2/58 (3.4%)
nd the control group (nonsilver). Statistic: 2 test.ndica
tion
8)
)
%)
)
%)
)
%)
)
%)
%)
.7%)
.2%)reduced by the silver graft (Fig 4).
ically
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remained significant for development of a graft infection:
wound healing disturbance and local revision. Therefore,
the local complication remained the most important factor
for developing a following graft infection. Silver did not
reduce the rate of infections in these cases (Fig 4, c, d; silver:
18.1% vs nonsilver 12.5%; P  .27).
DISCUSSION
Although silver-coated prostheses have been marketed
for routine use to prevent graft infection, only one study
has been published so far describing the “daily” use of
InterGard Silver grafts.9 This study was limited to their use
in the aortofemoral position and did not compare results
with a control group. The results presented here are the first
describing the application of silver prostheses in the femo-
rodistal position and comparing them with standard allo-
plastic grafts.
The two groups differed in basic parameters, which
may be attributed to the fact that the control group repre-
sented a longer period of time with the grafts, as many
nonsilver grafts had been implanted before the year 2001.
Patients in the silver group were older and included a
higher percentage of females, which may be explained by
demographic changes in recent years.10 Another sign of the
times is reflected in the lower number of patients in the
Fig 4. Infection rates for different local conditions. a, P
bypass in the groin). b, Existing bypass in the groin. c, Im
all groups, silver did not prevent an infection when com
the control group in a-d, the differences were not statist“newer” study group operated on in the stage of claudica-tion, especially for implantation of aortobifemoral prosthe-
ses. On the other hand, an increasing incidence of arterial
occlusive disease is reflected in the fact of more previous
procedures in the silver group, bypass implantations in
particular.
Our study reviewed all types of standard bypasses im-
planted for acute or chronic arterial occlusive disease. In
regard to intra- or postoperative complications, we saw no
statistically relevant differences between the two groups.
We did not note more typical intraoperative complications
like bypass occlusions or bleeding that could be attributed
to the special coating of the silver grafts. Staining of the
wound or wound secretion did not occur, although it is
known that silver ions released from devices may precipitate
as silver sulfide.11 These findings are in accordance with the
results of the study previously mentioned.9 The number of
lymphatic fistulas and wound healing disturbances seem
high in both groups. This may be explained by the relatively
broad definition summarizing lymphoceles and prolonged
wound secretion into lymphatic fistulas. A comparable in-
cidence of lymphatic fistula has been noted for aortofemo-
ral reconstructions in the literature (8.1%).12 Another study
described reducing 19% lymphatic complications to 10% by
using fibrin glue.13
Although mortality with intermittent claudication was
low (0.8%, none of the patients in the silver group), the rate
ing procedure (angioplasty, thrombendarterectomy, or
d wound healing. d, Revision for local complication. In
to the standard graft. Comparing the silver group with
significant. Statistic: 2 test.reced
paire
paredfor all patients was 5.4%. This rate seems quite high, but
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mortality rates of between 5.1% and 12%.14-17 We did not
see any significant differences between the silver and the
nonsilver group in our study.
Looking at overall patency, the silver group did not
perform and the nonsilver group. After correction for redo
procedures, indication, and bypass position, the patency
rates for the two groups were comparable. The primary
patency rates for the aortofemoral reconstructions in our
study were excellent. In contrast, patency rates for femoro-
distal operations were much lower. Similar results can be
found in the literature with unfavorable results for femoro-
crural and femoropedal alloplastic bypasses.16,18,19
The literature provides evidence that limb loss is fre-
quently the consequence in cases of bypass occlusion;20,21
therefore, patency and limb salvage rates should be compa-
rable. The limb salvage rate in our study was much better
than the patency rate, which means that the extremity can
be obtained even though the bypass is occluded. Currently
the concept is accepted that, in many cases, bypass function
is needed only to achieve wound healing. An occlusion after
wound healing may be irrelevant.
The results of the aorto-iliaco-femoral grafts for critical
limb ischemia were acceptable, with an overall limb salvage
rate of 79% after 5 years. Our results are comparable with
other publications describing limb salvage for aortofemoral
grafting for limb-threatening ischemia of 80-84%.22,23 For
femorodistal reconstructions, including femorocrural anas-
tomoses, the limb salvage rate is also comparable to other
studies reporting about 55-68% after 3 to 5 years.24-26
To prevent a graft infection, different procedures are
used in vascular surgery. Regarding the materials used,
grafts soaked with antibiotics have been employed with
some success in the last 15 years. Silver-coated prostheses
have been efficient in-vitro;1,27,28 however, in-vivo experi-
ments have produced controversial data.2-5 According to
the manufacturer, under clinical conditions the concentra-
tion of silver is reduced to 25% after 20 days; therefore, an
effective silver dose is available for only 2-4 weeks. This
should protect the bypass in case of previous groin surgery
or local complications such as wound healing impairment
or lymphatic fistula. After 4 weeks, the silver concentration
is so low that the InterGard Silver prosthesis should be
considered the same as any other polyester prosthesis.5 Of
the 59 infections noted in our study, only a minority took
place in the first 30 days after implantation. The mean time
until infection occurred was 321 days. According to the
literature, the majority (50%-65%) of all prosthetic infec-
tions will develop during the early postoperative inter-
val.29-31 As both groups developed graft infections quite
late, this discrepancy with the literature cannot be ex-
plained by the release of silver ions from the InterGard
Silver graft in the first 4 weeks.
Looking more closely at the details of graft infections,
one can see striking differences in the incidences. For
claudication and rest pain, the silver group performed
better than the control group. For aortofemoral procedures
(all indications), there was only one infection (1.1%), com-pared with 4.1% in the control group. These incidences can
be found in the literature; referring to aorto-iliaco-femoral
reconstructions, the incidence of prosthetic infections is
quite low, from 0.7% to 4.0% (Ricco et al9).
In contrast, for femorodistal prostheses implanted for
tissue loss and acute occlusion, the silver grafts had more
infections. In a recently published retrospective study, the
incidence of bypass infection was as high as 11%, indicating
an increase in recent years.8 Tissue loss has been described
as a risk factor for graft infection. Some groups have de-
scribed more graft infections in patients with peripheral
ulcer;29,32 additionally, in a recently published study,
Nguyen et al33 noticed that patients with tissue loss were
prone to more complications and infections.
In our univariate analysis, “typical” risk factors (previ-
ous procedures or local complications) were correlated with
development of a graft infection. For these situations, the
silver acetate prosthesis did not reduce the infection rate in
our study (Fig 3). This is also valid for the two factors
confirmed in the multiple regression analysis: wound heal-
ing disturbance and local revision. Although there are no
data in the literature describing a correlation between local
revision and subsequent graft infection, other authors re-
port a high number of infections in cases of compromised
wound healing. In an older study, Jamieson et al34 found
graft infections in 2.0% of patients without wound-healing
disturbances, but in 18.2% of the other group. In more
recent studies, wound infection and wound complications
have been shown to be independent factors in graft infec-
tion.35
Therefore, in our setting, the implantation of a silver-
acetate–coated polyester prosthesis did not protect against
subsequent graft infection in those patients with femoro-
distal bypass for PAOD stage 5 or 6, or those patients with
wound-healing problems or previous surgery.
Limitations of the study. As this is a retrospective
study, there may be a relevant error in the collection of basic
data from patients. Patients lost to follow-up amounted to
11% of the total. We do not know whether these patients
developed a graft infection and/or bypass occlusion. The
groups were not equal in terms of basic data and kinds of
surgeries. We tried to reduce that bias by analyzing sub-
groups.
CONCLUSIONS
The use of the InterGard Silver prosthesis is safe, and
the incidence of complications is comparable to that with
standard prostheses. Special side effects did not occur. With
regard to the standard performance parameters (patency
and limb salvage), these prostheses were comparable to
other materials. Looking at the development of consecutive
graft infections, we achieved good results in aortofemoral
reconstructions for every indication (including tissue loss),
which may suggest the effectiveness of prophylactic use. As
these results were not statistically significant, and the inci-
dence of graft infections in this localization is very low
anyway, it remains debatable if it is worth it to spend more
for the silver-acetate–coated graft.
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October 2009798 Larena-Avellaneda et alIn cases where implanting femorodistal grafts was done
for limb-threatening ischemia, or if a local complication
occurred, we found no protection against graft infection. In
our institution, the regimen has changed, and angioplasty is
now preferred even for long segment occlusions if autolo-
gous material is not available.
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